Cartesse AC™ will utilize the Cartesse™ platform technology to revolutionize how arthritis treatment and joint repair is performed. Large scale joint resurfacing is not currently possible and for many patients, total joint arthroplasty or palliative care is the only remedy for articular cartilage damage and degeneration. Although cell-based technologies are promising, they are currently limited to small cartilage defects, require long recovery times, and are extremely costly.
Cartesse AC™ aims to be the biomaterial solution for joint repair of ANY articular cartilage surface!
The ease of use and lower cost of a biomaterial therapy compared to cell-based methods, in addition to the tremendous potential for improving patient outcomes, make Cartesse AC™ an exciting potential solution for articular cartilage damage and disease.